MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Helping Obese Adolescents Lose Weight

Back to weightwatch Blogs list Cancer blog  


Subscribe To Weightwatch RSS Feed  RSS content feed What is RSS feed?

Helping Obese Adolescents Lose Weight

Helping Obese Adolescents Lose Weight
The weight loss medicine sibutramine, when combined with behavior treatment, allowed hundreds of very obese adolescents to lose an average of 14 pounds over a year, as per a multicenter study in the July 18 Annals of Internal Medicine. Adolescents in the study who received placebo (a sugar pill) gained four pounds over the year.

In addition to reductions in body mass index and weight, the treated adolescents had improvements in disease risk factors linked to obesity. They had lower levels of triglycerides and higher levels of high-density lipoprotein cholesterol, which are correlation to heart disease, and lower levels of insulin, a risk factor for diabetes. The only significant side effect was tachycardia, or rapid heart beat.

Eventhough sibutramine, sold under the brand name Meridia, is currently used in adults with obesity, "this is the first large multicenter trial of sibutramine for obese adolescents," said study leader Robert I. Berkowitz, M.D., chief of Child and Adolescent Psychiatry at The Children's Hospital of Philadelphia. "In fact, there have been few trials evaluating any obesity drugs in adolescents."

Behavior treatment alone, said Dr. Berkowitz, commonly provides only modest weight loss in adolescents, and thus medicine may provide an additional therapy option for this age group.

The study enrolled 498 severely obese adolescents, aged 12 to 16, in 33 outpatient clinics throughout the United States from 2000 to 2002. The patients were randomized into two double-blinded groups, one receiving sibutramine and one receiving a placebo, while both groups received behavior treatment.

Each therapy center had its own behavior treatment program, with flexible modification approaches that included self-monitoring of eating habits and physical activity, stress management, stimulus control, problem solving and social support. Counselors encouraged patients to increase their physical activity and reduce their sedentary behaviors, and provided nutritional counseling.

At the end of the study, the 281 adolescents in the therapy group lost an average of 14 pounds, while the 79 patients in the control group gained an average of four pounds. Body mass index (BMI) decreased by 9.4 percent in the therapy group in comparison to 1.2 percent in the control group. Patients in both groups gained height and matured sexually at the same rate.

The standard definition of overweight in adolescents commonly refers to those with a BMI greater than the 95th percentile for age and sex. This study focused on heavier patients, those with a BMI two units more than the 95th percentile, placing them at roughly the 97th percentile. Their mean weight was approximately 215 pounds.

At the end of the study, 33 percent of the patients who received sibutramine, in comparison to 7.6 percent in the control group, no longer had a BMI that was 2 units above the 95th percentile. Furthermore, 16.7 percent of the treated patients had their BMI drop below the 95th percentile (vs. 3.8 percent in the control group).

"At the end of a year of therapy, one-third of the adolescents who received medicine were no longer severely overweight, and one out of six who were treated dropped below the standard definition of being overweight," said Dr. Berkowitz. "We know that moderate weight loss in adults helps prevent or delay progression to type 2 diabetes. This may also be true in adolescents, eventhough this study cannot address that question."

As with any medication, cautioned Dr. Berkowitz, patients considering the use of sibutramine would need to consult with their physicians. Patients who take sibutramine require regular monitoring of pulse and blood pressure, and interactions with other specific medications may indicate that sibutramine should not be prescribed. In addition, the U.S. Food and Drug Administration does not currently approve using sibutramine in adolescents under age 16.

Because this study covered only one year of therapy, added Dr. Berkowitz, further investigation should analyze long-term weight management and health outcomes for adolescents with obesity. Other studies should focus on possible long-term risks of medicine versus risks of continued weight gain. He concluded, "Eventhough much research remains to be done, our findings are encouraging for clinicians, and may offer therapy options for obese adolescents for whom behavioral therapies alone are not successful."



Posted by: JoAnn    Source




Did you know?
The weight loss medicine sibutramine, when combined with behavior treatment, allowed hundreds of very obese adolescents to lose an average of 14 pounds over a year, as per a multicenter study in the July 18 Annals of Internal Medicine. Adolescents in the study who received placebo (a sugar pill) gained four pounds over the year.

Medicineworld.org: Helping Obese Adolescents Lose Weight

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.